c-Rel is overexpressed in several B-cell lymphomas and c-rel gene overexpression can transform primary chicken lymphoid cells and induce tumors in animals. Although c-Rel is generally a stronger transcriptional activator than its viral derivative v-Rel, its oncogenic activity is significantly weaker. Among the mutations acquired during c-Rel's evolution into v-Rel are deletion of c-Rel's transactivation domain 2 (cTAD2) and mutations in cTAD1. Given the critical role of the Rel TADs in cell transformation, we investigated how mutations in c-Rel's cTAD1 and cTAD2 contribute to its oncogenicity and that of v-Rel. Mutations in cTAD2 noticeably increased c-Rel's transforming activity by promoting its nuclear localization and gene-specific transactivation, despite an overall decrease in jB site-dependent transactivation potency. Conversely, substitution of vTAD by cTAD1 increased v-Rel's transactivation and transforming efficiencies, whereas its substitution by the stronger cTAD2 compromised activation of mip-1b but not irf-4 and was detrimental to cell transformation. These results suggest that the Rel TADs differentially contribute to genespecific activation and that an optimal range of transcription potency is necessary for efficient transformation. These findings may have important implications for understanding how Rel TAD mutations can lead to a more oncogenic phenotype.
c-Rel is overexpressed in several B-cell lymphomas and c-rel gene overexpression can transform primary chicken lymphoid cells and induce tumors in animals. Although c-Rel is generally a stronger transcriptional activator than its viral derivative v-Rel, its oncogenic activity is significantly weaker. Among the mutations acquired during c-Rel's evolution into v-Rel are deletion of c-Rel's transactivation domain 2 (cTAD2) and mutations in cTAD1. Given the critical role of the Rel TADs in cell transformation, we investigated how mutations in c-Rel's cTAD1 and cTAD2 contribute to its oncogenicity and that of v-Rel. Mutations in cTAD2 noticeably increased c-Rel's transforming activity by promoting its nuclear localization and gene-specific transactivation, despite an overall decrease in jB site-dependent transactivation potency. Conversely, substitution of vTAD by cTAD1 increased v-Rel's transactivation and transforming efficiencies, whereas its substitution by the stronger cTAD2 compromised activation of mip-1b but not irf-4 and was detrimental to cell transformation. These results suggest that the Rel TADs differentially contribute to genespecific activation and that an optimal range of transcription potency is necessary for efficient transformation. These findings may have important implications for understanding how Rel TAD mutations can lead to a more oncogenic phenotype. Keywords: Rel; NF-kB; transcription; transactivation; transformation c-rel is amplified in many lymphomas and some cases display accumulation of nuclear c-Rel protein (Rayet and Ge´linas, 1999; Barth et al., 2003; Savage et al., 2003; Gilmore et al., 2004) . Although c-Rel's contribution to tumor development remains unclear, Rel/NF-kB inhibition provokes apoptosis in lymphoma-derived cell lines, and overexpression of the c-rel gene transforms primary chicken lymphocytes to induce fatal tumors in animals (Nehyba et al., 1994; Hrdlickova´et al., 1994b; Gilmore et al., 2001; Fan et al., 2004; Feuerhake et al., 2005) . Transgenic expression of c-rel in mice can lead to mammary tumor formation, consistent with its activation in human breast cancer (Sovak et al., 1997; Cogswell et al., 2000; Romieu-Mourez et al., 2003) . However, c-Rel's transforming activity is significantly weaker than its truncated and mutated viral derivative v-Rel (Kralova et al., 1994; Nehyba et al., 1994; Hrdlickova´et al., 1994b; Gilmore et al., 2001; Fan et al., 2004) . Several mutations contribute to the increased oncogenicity of v-Rel, but the most significant change is the loss of 118 C-terminal amino acids that include c-Rel's transactivation domain 2 (cTAD2; Hrdlickova´et al., 1994b; Nehyba et al., 1994; Gilmore, 1999) . Consequently, v-Rel is a much weaker transcriptional activator than c-Rel on most NF-kB-dependent promoters (Kamens et al., 1990; Chen et al., 1999; Kralova et al., 2002) . cTAD2 is unique to c-Rel and contains 10 acidic residues. TAD1 is common to chicken c-Rel (cc-Rel; cTAD1) and v-Rel (vTAD), is rich in serines and threonines and is phosphorylated in transformed lymphocytes (Figure 1a) .
To further clarify the roles of TAD1 and TAD2 in c-Rel's oncogenicity and its evolution into the potently transforming v-Rel, we investigated their contribution to transcription and transformation. The intrinsic activity of vTAD, cTAD1 and cTAD2 was assessed by fusion to a yeast GAL4 DNA-binding domain ( Figure 1a ). cTAD2 was the most potent, and vTAD was significantly weaker than cTAD1 (Figure 1b) . Asp/ Glu-to-Ala substitutions showed that certain acidic residues contribute differently to cTAD2's transactivation potential (Figure 1b) . Although mutation of all acidic residues in cTAD2 abolished its transcriptional activity (cc-Rel-A4), mutants cc-Rel-A1 and -A2 with six acidic residues showed attenuated transactivation (B37 and 17% of GAL4-cTAD2; Figure 1b) . Reinstating a single aspartate at the first position in cc-Rel-A2 (aa 534) restored activation to B37% of GAL4-cTAD2 (cc-Rel-A3). When reconstructed in cc-Rel, cTAD2 mutations significantly decreased its strong transactivation potential on IL6kBLUC despite roughly equivalent DNA binding (cc-Rel-A1, -A2 and -A3; Figure 2a -c). cc-Rel-A4 failed to transactivate, although it retained an intact cTAD1. The mechanistic basis for its deficiency remains to be determined. Consistent with the weaker transactivation capacity of GAL4-vTAD compared to GAL4-cTAD1 (B40%; Figure 1b) , substitution of c-Rel's cTAD1 with vTAD reduced its transactivation potential to B43% of c-Rel's ( Figure 2b ; cc-Rel-swvTAD). These data indicate that cTAD1 and cTAD2 work together to influence c-Rel's transcriptional activity and that mutations can significantly decrease cTAD2's transactivation potency.
Importantly, mutations that diminished cTAD2's activity markedly improved c-Rel's transforming ability, although the overall number of colonies forming in agar varied between assays as is typical for these experiments (cc-Rel-A1, -A2, -A3; Figure 2d ). Likewise, TAD1 exchange mutant cc-Rel-sw-vTAD, with an B57% decrease in transcriptional potency compared to c-Rel, displayed enhanced transforming activity. In contrast, cc-Rel-A4 failed to transform. These data indicate that reducing c-Rel's strong transcriptional capacity markedly improves its transforming potential, although a minimum threshold of activation is necessary for transformation. The improved transforming activity of cc-Rel-A1, -A2, -A3 and -sw-vTAD was correlated with their increased nuclear localization and reduced relative association with endogenous IkBa compared to cc-Rel (Figures 2e-g and 4) . Although this alone could not fully explain their different transforming efficiencies, we found that cc-Rel-A1, -A2, -A3 and sw-vTAD differentially activated kB site-dependent gene expression in infected cells (Figure 2h ). For example, activation of mip-1b, that transformation-defective v-Rel mutants fail to induce (Petrenko et al., 1997) , was more closely correlated with their increased transforming activity than activation of irf-4 (Figure 2h ; Hrdlickova´et al., 2001). Thus, despite decreasing c-Rel's intrinsic transactivation potency on luciferase reporters, TAD1 and TAD2 mutations can promote gene-specific activation and markedly improve its transforming potential.
When substituted in v-Rel, cTAD1 and cTAD2 significantly increased transcription without affecting DNA binding (Figure 3a-c) . Their activity was higher than that of vTAD mutant S438,439D whose transforming activity is enhanced compared to v-Rel (Rayet et al., 2003) . Although enhanced transactivation by v-Rel-sw-cTAD1 was accompanied by a sharp increase in transformation compared to v-Rel, transformation by v-Rel-sw-cTAD2 was dramatically lower despite its significantly higher transactivation potential (Figure 3d ). Thus, mutations that increase v-Rel's transactivation ability within a suitable range further enhance its already high transforming activity, but those that increase its activation potency beyond a certain level are detrimental for transformation. Substitution of v-Rel's vTAD with c-Rel's cTAD2 prompted its partial cytoplasmic relocalization, which is likely responsible for its decreased transforming activity (v-Rel-swcTAD2, Figure 3e ). However, its relative association with IkBa was unaffected compared to v-Rel, suggesting that other IkB isoforms might be involved (Figures 3g  and 4) . However, the lack of antibodies to chicken IkBb and IkBe precludes their investigation at this time. Contrary to cTAD2, substitution of vTAD with cTAD1 had no adverse effect on v-Rel's localization but it increased its ability to activate expression of mip-1b and irf-4, as did mutation S438,439D (v-Rel-sw-cTAD1; Figure 3e and h). This coincided with markedly improved transformation. In contrast, its substitution by cTAD2 was detrimental to cell transformation and compromised gene-specific activation, as illustrated by a sharp decrease in mip-1b expression despite stronger transcriptional potency in luciferase assays (v-Rel-swcTAD2; Figure 3h ). Together with our analysis of c-Rel mutants, these data underscore the important role of cTAD2 in the subcellular localization of Rel proteins and indicate that particular mutations in the Rel TADs can affect gene-specific expression and be a determining factor for cell transformation. Our findings agree with reports suggesting a role for c-Rel's C-terminus in its cytoplasmic anchoring and negative regulation by IkBa (Figure 4 ; Hannink and Temin, 1989; Capobianco et al., 1990; Diehl et al., 1993; Starczynowski et al., 2003; Iwai et al., 2005) . cTAD2 mutations that dampen negative feedback by IkBa are likely to enable long-lasting activation of genes important for cell transformation, as seen for ch-IAP1 (Kralova et al., 2002) . cTAD2 mutations may also impart additional advantages, as prior work attributed a cytotoxic/cytostatic effect to the C-terminal 16 amino acids of cc-Rel (Nehyba et al., 1994) . cTAD2 is absent in v-Rel and is commonly deleted in cc-Rel-induced tumors in animal models (Kralova et al., 1994; Hrdlickova´et al., 1994a; Nehyba et al., 1997; Gilmore et al., 2001) . Moreover, homozygous deletion of c-rel's C-terminus induces lymphoid cell hyperplasia in mice, and deletion or mutation of human c-Rel's TAD subdomains enhances its transforming activity (Carrasco et al., 1998; Starczynowski et al., 2003 Starczynowski et al., , 2005 . Our data suggest that selective pressure for increased oncogenicity centers on the loss of cTAD2's transactivation function. 
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RelA is commonly involved in human tumors due to constitutive activation of IKK that promotes IkBa degradation, but genomic alterations appear to be the preferred mode of activation for c-Rel (Rayet and Ge´linas, 1999) . In addition to c-rel gene amplification and/or overexpression, other less frequent alterations are also observed in B-cell lymphomas (Gilmore et al., 2004) . These include C-terminal truncation in primary Hodgkin's lymphoma, and truncation and fusion to non-rel gene sequences in the diffuse large B-cell lymphoma-derived cell line RC-K8 (c-rel-nrg; Kalaitzidis et al., 2002; Barth et al., 2003) . A serine TAD mutation was identified in a T lymphoblastic Jurkat cell line that failed to respond to activation by TNFa (S471N; Martin and Fresno, 2000; Starczynowski et al., 2005) . This mutation altered c-Rel's ability to activate certain kB sitedependent promoters and displayed enhanced transforming activity compared to wild type (Starczynowski et al., 2005) . Given these findings and ours, it will be interesting to see if particular c-Rel TAD mutations will emerge as a novel means to enhance its contribution to human cancer (Supplementary material).
